BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

MVC obtains Taiwan government subsidy for initiating Ph 1 trial of COVID-19 vaccine

13 October 2020 | News

The subsidy will be released at agreed-upon milestones in the total amount of up to NT$ 472 M

Taiwan based Medigen Vaccine Biologics Corporation (MVC), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax Technologies Corporation, a US based biopharmaceutical company focused on developing and commercializing novel vaccines, has announced that MVC has obtained a Taiwan government subsidy for successfully initiating a Phase 1 clinical trial in Taiwan.

The first participant in MVC's Phase 1 clinical trial was dosed with MVC's COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant at National Taiwan University Hospital in early October. The subsidy will be released at agreed-upon milestones in the total amount of up to NT$ 472 million (US$ 16.4 million).

MVC's Phase 1 study is an open-label, single-center, staggered dose-escalation study intended to assess the safety and immunogenicity of the stable prefusion form of SARS-CoV-2 recombinant spike protein S-2P at three dose levels (low, medium and high) adjuvanted with CpG 1018 plus alum, in approximately 45 healthy subjects 20 to 50 years of age.

MVC's subunit vaccine is based on the stable prefusion form of the SARS-CoV2 recombinant spike protein with a global technology license from the US Vaccine Research Center at the National Institutes of Health (NIH).